NTRA · Equity Scorecard · Methodology: 35% Valuation · 35% Financial Health · 30% Growth/Catalysts · Data as of Apr 2026
Healthcare Molecular Diagnostics April 2026
NTRA
Natera, Inc. · NASDAQ · Austin, TX
Price (Apr 18, 2026)
$208.40
52W: $131.81 — $256.36 · Mkt Cap ~$35B
Overall Score
64/100
Composite — Valuation 35% · Health 35% · Growth 30%
Watchlist / Add on Meaningful Weakness
Score Breakdown
Valuation / Entry
17/35
Financial Health
22/35
Growth / Catalysts
25/30
Key Metrics — FY2025 Actuals + 2026 Guidance
Revenue FY25
$2.31B
+35.9% YoY
Gross Margin
64.7%
Q4: 66.9%
EV / Rev FY26E
12.9x
FY25: 14.9x
Net Cash
$844M
D/E: 0.16
2026 Rev Guide
$2.62–2.70B
+14–17% YoY
Op. Cash Flow
+$108M
First positive year
Net Loss FY25
-$208M
EPS: -$1.52
MRD Volume Q4
225K
+56% YoY
52-Week Price Range
52W Low: $131.81 Current: $208.40 — 61% of range 52W High: $256.36
Low -19% from peak · -32% needed to reach 52W low High
Signal Flags
✓ GM 66.9% expanding ✓ Cash flow inflection 2025 ✓ 50%+ US oncologist adoption ✓ Net cash $844M, no leverage ✓ Multiple new indications pipeline ⚠ EV/Rev 12.9x — premium valuation ⚠ Growth decelerating: 36% → 17% 2026 ⚠ True-up dependency (~3-4% of GM) ✗ GAAP loss-making, EPS -$1.52 ✗ Class action certified Apr 2026 ✗ Dilution +11% shares/year ✗ ROE/ROIC still negative
Investment Thesis

NTRA is building the dominant MRD platform in oncology. Signatera is becoming standard of care — >50% of US oncologists ordered a test in Q4 2025. The economics are improving: gross margins are expanding sequentially (+660bps in 2 years) as scale and better reimbursement take hold. 2025 was the first year of positive operating cash flow — the inflection most growth investors were waiting for. The TAM is massive (billions of cancer surveillance tests annually) and underpenetrated globally. International expansion and new indications (colorectal, organ health) add optionality.

Primary Risk

Class action certified April 2026 is the key overhang. The lawsuit (period 2020-2022) alleges deceptive billing practices drove revenue growth. If proven, it creates financial liability and reputational damage. Separately, reimbursement is a structural risk: new indications need payor coverage expansion, and true-ups (3-4% of gross margin) are non-recurring and declining. Share dilution at 11%/year is the hidden tax on equity returns. Premium EV/Rev multiple leaves no margin of safety if growth disappoints.

NTRA · Deep Dive — Financials · Valuation · Monitoring Triggers
Financial History — Annual
Period Revenue YoY Growth Gross Margin Net Income Op. Cash Flow EPS
FY2022 $770M +41% 48.2% -$572M -$402M -$5.02
FY2023 $1,084M +41% 52.1% -$459M -$280M -$3.83
FY2024 $1,697M +57% 60.3% -$190M -$22M -$1.38
FY2025 $2,306M +36% 64.7% -$208M +$108M -$1.52
2026E $2,640–2,700M +15–17% 63–65% Loss narrowing Positive Est. -$0.4–0.8
Quarterly Momentum — 2025
Quarter Revenue YoY Growth Gross Margin MRD Clinical Units Beat/Miss
Q1 2025 $530M +36% 63.3% 161K (+51% YoY) Beat
Q2 2025 $555M +35% 63.1% 181K (+51% YoY) Beat
Q3 2025 $555M +33% 64.9% 202K (+52% YoY) Beat
Q4 2025 $666M +40% 66.9% 225K (+56% YoY) Beat +$6M vs pre-ann.
Valuation Framework — Revenue Multiple Approach
Metric Current Bull Case Base Case Bear Case Note
EV / Rev FY26E 12.9x 15x → $310 12x → $248 9x → $186 Base at consensus revenue
EV / Rev FY27E — 12x → $350+ 10x → $290 7x → $200 Rev ~$3.1B assumed at 15%
EV / GM FY26E ~20x 24x → $290 18x → $218 14x → $169 GM ~$1.7B at 64%
Analyst Avg PT $259 $300 (high) — $190 (low) 18 Buy / 0 Sell consensus
Legal Risk — Class Action

Class action certified April 2026 — Class period: Feb 26, 2020 – Apr 19, 2022. Allegation: Natera relied on deceptive sales and billing practices to drive revenue growth during this period. Law firms: Kessler Topaz Meltzer & Check / Bernstein Litowitz Berger & Grossmann. Assessment: This is a material overhang but relates to a historical period. Natera has been operating cleanly since. Financial exposure is unknown but likely manageable vs. $35B market cap. Monitor: any settlement size, management commentary on Q2 2026 earnings call. Does not change the fundamental thesis but reduces the conviction multiple warranted at current prices.

Key Catalysts — 2026
May 7, 2026 Q1 2026 Earnings — Revenue guidance confirmation, GM trajectory, class action commentary Earnings
H1 2026 Expanded MolDX coverage — Additional reimbursement for new indications drives ASP step-up Reimbursement
2026 Foresight Diagnostics integration — Adds ctDNA-based early cancer detection capabilities M&A
2026 DEFINE trial (colorectal early detection) — Key data readout for Latitude expansion Clinical
2026 Signatera Japan launch + structural variants — International expansion, new clinical utility Commercial
2026 Path to GAAP profitability — If SG&A held stable and GM holds 63-65%, EPS breakeven possible in 2027 Fundamental
Monitoring — Add Triggers
Price ≤ $175–185 — EV/Rev FY26E ~10x, historically attractive entry for a 35%+ compounder pre-profitability inflection
Class action settlement announced with manageable financial terms — removes overhang, re-rate likely
Q1 2026 earnings: GM ≥ 64%, MRD volume ≥ 240K — confirms trajectory intact vs. seasonal Q1 softness
MolDX coverage expansion confirmed for additional cancer types — structural ASP tailwind
Monitoring — Exit / Reduce Triggers
Revenue guide cut or miss ≥ 5% — at 12.9x EV/Rev, even small misses produce violent multiple compression
GM fails to hold 63% — true-up dependency exposes; core GM ex true-ups must remain ≥ 60%
Class action adverse ruling with large financial exposure (>$500M) — material dilution risk
MRD volume growth decelerates below 35% YoY — signals physician adoption saturation in core US market